The Cicada COVID variant, identified as BA.3.2, exhibits symptoms similar to previous strains. Health experts are monitoring its spread.
The wider picture
The BA.3.2 variant, commonly referred to as the Cicada variant, is a descendent of the BA.3 omicron subvariant that emerged in 2022. First identified in South Africa in November 2024, this variant has raised concerns among health officials due to its rapid spread across various countries. As of now, BA.3.2 has been detected in over 20 nations, including 25 states in the United States, where its presence is currently on the rise.
One of the most notable features of the Cicada variant is its genetic makeup. It carries approximately 70 to 75 mutations in its spike protein, which is significant as these mutations can potentially affect how the virus interacts with the immune system and respond to vaccines. However, current evidence suggests that BA.3.2 does not cause more severe illness compared to earlier variants, a point emphasized by health experts.
Common symptoms associated with the Cicada variant include cough, fever or chills, sore throat, congestion, shortness of breath, loss of smell or taste, fatigue, headache, and gastrointestinal issues such as diarrhea or vomiting. These symptoms largely mirror those seen in previous COVID-19 strains, particularly the Omicron variants. Dr. Adolfo García-Sastre noted, “There’s no evidence that BA.3.2 is causing more severe disease or hospitalizations in countries where it’s more widespread.” Most cases appear to be mild to moderate, resembling flu-like illness, especially among vaccinated individuals.
Despite the presence of multiple mutations, health authorities have indicated that current vaccines are expected to provide strong protection against severe disease, even if breakthrough infections occur. Vaccination remains a critical tool in managing the impact of the Cicada variant, and health experts recommend that individuals stay up to date with their vaccinations and take precautions in crowded settings.
As the Cicada variant continues to spread, health officials are actively monitoring its impact. Observers note that while the symptoms linked to the Cicada variant remain largely consistent with previous COVID-19 strains, the situation is fluid and requires ongoing attention. Health experts have reiterated that most cases can be managed at home with rest and hydration, and there are no new or unusual signs reported so far.
In summary, the emergence of the Cicada variant underscores the importance of vigilance in public health measures. As the variant spreads, health authorities are committed to tracking its progression and understanding its implications for public health. The situation remains dynamic, and details remain unconfirmed as new data emerges.
